September 12, 2021. Hydroxychloroquine for Post Exposure Prophylaxis May Reduce COVID-19 Infection in Young People and if it is Initiated Early

in STEMGeekslast month

picture_hive_covid_news_updates.jpg

This following article(not peer reviewed yet, in pre-print) is a
, placebo-controlled, study which gave hydroxychloroquine (HCQ) or placebo to people who were exposed to COVID-19. In addition, it divided the exposure in early (0-3 days from exposure) and late (4 days or more from exposure) and by age.

The results show that there may be an statistically significant difference favoring HCQ use in post exposure prophylaxis of people younger than 45 years old and who started HCQ early.

Any information or statement present in this post does not replace your health care provider’s advice or treatment. This blog does not provide medical advice, prescribe medications or therapies, or diagnose conditions, it only expresses an opinion. If you have a health-related question or condition, confer with your healthcare provider.
Sort:  

Congratulations @secondmedicalop! You have completed the following achievement on the Hive blockchain and have been rewarded with new badge(s) :

You published more than 250 posts.
Your next target is to reach 300 posts.

You can view your badges on your board and compare yourself to others in the Ranking
If you no longer want to receive notifications, reply to this comment with the word STOP

To support your work, I also upvoted your post!

Check out the last post from @hivebuzz:

Hive Power Up Month - Feedback from Day 12

If I read that article correctly (and I may not have) this was a reinterpretation of the data from one or two other studies that were used by the FDA to show HCQ didn't work that included "missing data" (not sure what data was missing though). The whole thing sounds a little odd to me. It will be interesting to see how peer review goes.

Yes, peer review is important. Also studies with similar methodologies.